|Description:||Rabbit polyclonal antibody to Tuberin/TSC2.|
|Applications:||WB, IHC, IF|
|Dilutions:||WB: 1:200 - 1:500, IHC: 1:50 - 1:100, IF: 1:50 - 1:100.|
|Immunogen:||A synthetic peptide of human TSC2.|
|Formulation:||Supplied in Phosphate Buffered Saline, pH 7.30, with 0.02% Sodium Azide and 50% Glycerol.|
|Storage:||Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.|
|Function:||In complex with TSC1, this tumor suppressor inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling. Acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1. May also play a role in microtubule-mediated protein transport. Also stimulates the intrinsic GTPase activity of the Ras-related proteins RAP1A and RAB5.|
|Tissue Specificity:||Liver, brain, heart, lymphocytes, fibroblasts, biliary epithelium, pancreas, skeletal muscle, kidney, lung and placenta.|
|Involvement in Disease:||Tuberous sclerosis 2: An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.
Lymphangioleiomyomatosis: Progressive and often fatal lung disease characterized by a diffuse proliferation of abnormal smooth muscle cells in the lungs. It affects almost exclusively young women and can occur as an isolated disorder or in association with tuberous sclerosis complex.
|Post-Translational Modification:||Phosphorylation at Ser-1387, Ser-1418 or Ser-1420 does not affect interaction with TSC1. Phosphorylation at Ser-939 and Thr-1462 by PKB/AKT1 is induced by growth factor stimulation. Phosphorylation by AMPK activates it and leads to negatively regulates the mTORC1 complex. Phosphorylated at Ser-1798 by RPS6KA1; phosphorylation inhibits TSC2 ability to suppress mTORC1 signaling. Phosphorylated by DAPK1.|
|Cellular Location:||Cytoplasm. Membrane.
At steady state found in association with membranes.
Protein phosphatase 1, regulatory subunit 160 Antibody
TSC4 gene, formerly Antibody
TSC4, formerly Antibody
Tuberous sclerosis 2 Antibody
Tuberous sclerosis 2 protein Antibody
Tuberous sclerosis 2 protein homolog Antibody
|Information:||Target information shown above is from the UniProt Consortium.|